Project Grant F32HL178155
Award Date
6/20/25
Completion Date
1/31/28
Dollars Obligated
$155K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Cambridge, MA 02142, USA
Similar Awards
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $1,204,160 to evaluate the AMPK-BACH1-NRF2 pathway as a potential therapeutic target for inherited dilated cardiomyopathy (DCM). The primary goal is to determine if activating this signaling pathway can restore contractile function in multiple forms of inherited DCM, including those caused by mutations in myofilament and...
This $1,862,169 Project Grant, awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), will fund interdisciplinary research at Massachusetts General Hospital (MGH) to investigate the mechanism of myocardial fibrosis induced by mitral valve prolapse (MVP). The key products and services to be delivered include: Developing a surgical MVP model in sheep to quantify the progression of MVP-induced left ventricular fibrosis over...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $625,799 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center. The award, with a project period from September 1, 2024 to June 30, 2028, will support research to understand the role of cellular senescence in trisomy 21 (Down syndrome) lung disease. The grant will fund the use of developing human lung tissues, mesenchymal...
This federal Project Grant award of $2,251,975 from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) will support research to identify unrecognized genetic causes of congenital heart disease (CHD). The project, led by Brigham & Women's Hospital Inc., aims to assess the contribution of rare and de novo non-coding and coding variants to unexplained cases of CHD. The research will utilize whole exome/genome sequencing data from a large cohort of CHD...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research Program (CFDA 93.837) provides $374,100 to the University of California, San Diego (UCSD) to conduct research on the regulatory mechanisms of desmosomal protein expression in arrhythmogenic cardiomyopathy (ACM). The goal is to characterize how dysregulation of desmosomal proteins contributes to ACM disease progression and identify potential therapeutic targets. Key...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $618,045 to the University of Arizona to conduct research on understanding the molecular mechanisms behind diastolic dysfunction in hypertrophic cardiomyopathy (HCM). The key objectives are to: 1) fully characterize the specific functional domains of the cardiac thin filament linked to the regulation of cardiac relaxation, and...
This federal Project Grant award, provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), supports research investigating the role of the unfolded protein response in genetic dilated cardiomyopathy (DCM). The $159,512 grant, awarded to The Leland Stanford Junior University, will examine how impaired protein homeostasis leads to cardiac dysfunction in DCM using patient-derived induced pluripotent stem cell-derived...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $736,574 to the Icahn School of Medicine at Mount Sinai to investigate the role of the RNA-binding protein DDX3X in heart development and disease. The award aims to uncover the direct and functionally relevant targets of DDX3X, determine the cellular phenotype of DDX3X-deficient embryos, and elucidate genotype-phenotype correlations in...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), will provide $756,039 to the Regents of the University of Michigan to conduct research on genetic factors that influence the severity of cardiomyopathies. The key objectives are to: 1) Quantify the gene expression effects of all possible single nucleotide variants (SNVs) in the cis-regulatory elements (CREs) of the MYBPC3 and DSP genes, which...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $153,512 to the University of California, San Diego (UCSD) to investigate how tissue elasticity and viscosity modulate macrophage-fibroblast signaling in cardiac fibrosis. The key objectives are to: 1) Develop an engineered cell culture system to study the independent and dynamic effects of tissue elasticity and viscosity on macrophage...